A Candid Outlook on Global Cancer Vaccines Market


Cancer Vaccines Market

Cancer Vaccines – A Brief History and Market Summary

Cancer vaccines can be defined as those vaccines that treat existing cancer or prevents the development of cancer and vaccines that treat existing cancer are known as therapeutics cancer vaccines. Majority of vaccines can be broadly classified into prophylactic and therapeutic vaccines with the former being used for the prevention of cancer whereas the therapeutic vaccines are used for the treatment of disease.

Ever since Dr. William Coley made the first attempt to stimulate immune system for improving a cancer patient’s condition by intratumoral injections of inactivated Streptococcus pyogenes and Serratia marcescens (known as Coley’s Toxin) in 1891- the global cancer vaccines market has grown substantially. The field of immunology as we see it today has developed into a highly sophisticated specialty with the recent advances in cancer immunology having achieved the clinical proof of concept of therapeutic cancer vaccine. The global cancer vaccines market was valued worth US$2.1 billion in 2015 with a CAGR of 18% for a period up to 2021.

As per the report of the World Health Organization (WHO) in 2016, about 1.7 million new cancer cases were reported in the United States of America alone. The annual incidence of cancer globally is projected to increase to 24 million by the end of 2035 creating a demand for cancer vaccines. Most of the cancer vaccines available in the global cancer market address specific cancer types and are therapeutic vaccines these include GVAX, AC vaccine, Prostvac, CDX11 etc. The market for cancer vaccines is much smaller when compared with cancer therapeutic categories. Therefore, to tap the market many global companies are hugely investing in the development and research of cancer vaccines.

Global Cancer Vaccines Market – Recent trends and insights

The global cancer vaccines market is in an upbeat mode with the various key factors driving the global cancer market growth that include-

  • Rise in the prevalence of human papilloma virus (HPV) infections leading to cancers
  • Increase in the administration of prophylactic cancer vaccines
  • Surge in the investment in the development of cancer vaccines by manufacturers and through government funding
  • Launching of novel cancer vaccines in the market
  • The rise in Hepatitis B virus (HBV) infections leading to liver cancer in many people has created a demand for HBV vaccines from the global cancer vaccines market.
  • Rise in the aging population
  • Increasing health care expenditure

The research and innovation for cancer vaccines is taken at a much faster pace than ever before especially for prophylactic vaccines with the Merck and GSK emerging as the leaders in the prophylactic cancer vaccine segment. The research and innovation for cancer vaccines are highly robust with several trials being carried out in the field of therapeutic vaccines segment. The therapeutic vaccines currently account for 12% share in the United States of America’s Cancer Vaccine market with the share expected to increase in the coming decades due to high focus on developing therapeutics for various types of cancer.

Majority of medical research firms and global pharmaceutical firms are investing huge funds in the development of new cancer vaccines thereby heating up the global cancer vaccine market in the form of competition among various pharmaceutical firms.

Segmentation of Global Cancer Vaccines Market – A short study

The global cancer vaccines market as per reputed market research reports is segmented broadly into Technology, Type, End Users, and Geography. Under Technology Segment – the cancer vaccines are broadly classified into-

  • Subunit Vaccines
  • Conjugate Vaccines
  • Inactivated Vaccines
  • Recombinant Vector Vaccines
  • Toxoiod Vaccines
  • Synthetic Vaccines
  • Dendritic Cell Vaccines
  • Live Attenuated Vaccines

Based on Type of cancer vaccines – the market is segmented as-

  • Preventive Vaccines
  • Therapeutic Vaccines
  • Disease Indication Vaccines
  • Cervical Cancer Vaccines
  • Others

Based on End User – the global cancer vaccines market is divided into categories such as

  • Pediatrics
  • Adults

Geographic segmentation of the cancer vaccines are classified under the heads as-

  • North America
  • Europe
  • Latin America
  • The Middle East and Africa
  • Asia-Pacific

North America has the major share in the global cancer vaccines market with the United States leading the pack in terms of its market share. However, the Asia-Pacific region is poised to grow at a higher CAGR in the coming decades.

Click to request sample of the report

Share this post:

Recent Posts

Leave a Comment

+ 25 = 30